Stock Scorecard
Stock Summary for KalVista Pharmaceuticals Inc (KALV) - $16.13 as of 3/2/2026 8:23:00 AM EST
Total Score
7 out of 30
Safety Score
26 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for KALV
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for KALV
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for KALV
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for KALV
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for KALV (26 out of 100)
| Stock Price Rating (Max of 10) | 6 |
| Historical Stock Price Rating (Max of 10) | 4 |
| Stock Price Trend (Max of 10) | 10 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 6 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Latest News for for KALV
Financial Details for KALV
Company Overview |
|
|---|---|
| Ticker | KALV |
| Company Name | KalVista Pharmaceuticals Inc |
| Country | N/A |
| Description | KalVista Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, discovers, develops, and markets small-molecule protease inhibitors for illnesses with unmet needs. The company is headquartered in Cambridge, Massachusetts. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 10/31/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 16.13 |
| Price 4 Years Ago | 6.76 |
| Last Day Price Updated | 3/2/2026 8:23:00 AM EST |
| Last Day Volume | 729,671 |
| Average Daily Volume | 703,823 |
| 52-Week High | 19.00 |
| 52-Week Low | 9.23 |
| Last Price to 52 Week Low | 74.76% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 26.08 |
| Sector PE | 46.86 |
| 5-Year Average PE | -3.75 |
| Free Cash Flow Ratio | 3.35 |
| Industry Free Cash Flow Ratio | 12.68 |
| Sector Free Cash Flow Ratio | 25.71 |
| Current Ratio Most Recent Quarter | 7.22 |
| Total Cash Per Share | 4.82 |
| Book Value Per Share Most Recent Quarter | 0.34 |
| Price to Book Ratio | 44.32 |
| Industry Price to Book Ratio | 50.08 |
| Sector Price to Book Ratio | 52.77 |
| Price to Sales Ratio Twelve Trailing Months | 531.34 |
| Industry Price to Sales Ratio Twelve Trailing Months | 38.92 |
| Sector Price to Sales Ratio Twelve Trailing Months | 22.39 |
| Analyst Buy Ratings | 7 |
| Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
| Total Shares Outstanding | 50,546,000 |
| Market Capitalization | 815,306,980 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -44.85% |
| Reported EPS 12 Trailing Months | -3.94 |
| Reported EPS Past Year | -2.04 |
| Reported EPS Prior Year | -3.69 |
| Net Income Twelve Trailing Months | -210,313,000 |
| Net Income Past Year | -183,444,000 |
| Net Income Prior Year | -126,644,000 |
| Quarterly Revenue Growth YOY | 30.70% |
| 5-Year Revenue Growth | -100.00% |
| Operating Margin Twelve Trailing Months | -336.30% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 243,497,000 |
| Total Cash Past Year | 98,644,000 |
| Total Cash Prior Year | 31,789,000 |
| Net Cash Position Most Recent Quarter | 104,469,000 |
| Net Cash Position Past Year | 98,644,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 139,028,000 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 0.11 |
| Total Stockholder Equity Past Year | 95,391,000 |
| Total Stockholder Equity Prior Year | 206,582,000 |
| Total Stockholder Equity Most Recent Quarter | 16,999,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -161,018,999 |
| Free Cash Flow Per Share Twelve Trailing Months | -3.19 |
| Free Cash Flow Past Year | -153,341,000 |
| Free Cash Flow Prior Year | -89,674,000 |
Options |
|
| Put/Call Ratio | 0.50 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.09 |
| MACD Signal | 0.02 |
| 20-Day Bollinger Lower Band | 11.03 |
| 20-Day Bollinger Middle Band | 14.71 |
| 20-Day Bollinger Upper Band | 18.40 |
| Beta | -0.35 |
| RSI | 55.32 |
| 50-Day SMA | 13.46 |
| 150-Day SMA | 11.74 |
| 200-Day SMA | 11.06 |
System |
|
| Modified | 3/3/2026 2:38:53 AM EST |